The CRC Blueprint

My scientific approach to my own cancer – shared with you.

United States

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 · randomised · 408 people · 62 sites in United States · Recruiting now

August 7, 2026
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Phase 2 · randomised · 482 people · 14 sites in 5 countries · Recruiting now

August 7, 2026
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now

August 7, 2026
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Phase 3 · randomised · 700 people · 35 sites in 8 countries · Recruiting now

August 7, 2026
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer

Phase 3 · randomised · 1,020 people · 21 sites in 6 countries · Recruiting now

August 7, 2026
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3 · randomised · 400 people · 366 sites in 25 countries · Recruiting now

August 7, 2026
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Phase 3 · randomised · 364 people · 187 sites in 2 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now

August 7, 2026
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 · randomised · 700 people · 254 sites in 21 countries · Recruiting now

August 7, 2026